ACAD Stock Forecast & Price Target

Acadia Pharmaceuticals is supported by two underappreciated commercial franchises, with Nuplazid still growing steadily and Daybue gaining momentum from Stix uptake, including more than 50% of U.S. patients now on the Stix formulation and FY-'26 revenue guidance raised to $1.265B-$1.295B. The company also ended 3Q26 with $976M in cash and showed operating discipline as R&D and SG&A came in below expectations, strengthening the balance sheet and reducing near-term execution risk. Beyond the base business, remlifanserin and ACP-211 provide meaningful pipeline optionality, while the company’s sub-$4B valuation appears to leave limited downside given the existing revenue stream and potential for additional growth in 2027.

Acadia Pharmaceuticals is exposed to multiple fundamental headwinds, led by the risk that Daybue uptake disappoints and Nuplazid growth in PDP flattens, which would pressure the company’s two core revenue franchises. The investment case is further weakened by IP uncertainties, worsening reimbursement and high government payer exposure, potential regulatory or clinical delays, and the possibility of a safety signal that could hinder adoption or even force removal from the market. Its pipeline also carries meaningful execution risk, as ACP-204 in ADP, the Ph 3 schizophrenia program, and ACP-101 may fail or stall, while competition, financing needs, and the inability to secure value-creative partnerships could add further downside.